0001209191-23-004148.txt : 20230119
0001209191-23-004148.hdr.sgml : 20230119
20230119214843
ACCESSION NUMBER: 0001209191-23-004148
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230117
FILED AS OF DATE: 20230119
DATE AS OF CHANGE: 20230119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Andriole Michael T.
CENTRAL INDEX KEY: 0001698751
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35867
FILM NUMBER: 23538786
MAIL ADDRESS:
STREET 1: C/O ENDOCYTE, INC.
STREET 2: 3000 KENT AVENUE, SUITE A1-100
CITY: WEST LAFAYETTE
STATE: IN
ZIP: 47906
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHIMERIX INC
CENTRAL INDEX KEY: 0001117480
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330903395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919.806.1074
MAIL ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-17
0
0001117480
CHIMERIX INC
CMRX
0001698751
Andriole Michael T.
2505 MERIDIAN PARKWAY, SUITE 100
DURHAM
NC
27713
0
1
0
0
Chief Business Officer and CFO
Common Stock
2023-01-17
4
A
0
32175
0.00
A
294899
D
Stock Option (Right to Buy)
1.97
2023-01-17
4
A
0
192825
0.00
A
2033-01-16
Common Stock
192825
192825
D
The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 8,043 shares subject to the RSUs will vest on the one-year anniversary of the date of grant, 8,043 shares subject to the RSUs will vest on the second-year anniversary of the date of grant, 8,043 shares subject to the RSUs will vest on the third-year anniversary of the date of grant, and 8,046 shares subject to the RSUs will vest on the fourth-year anniversary of the date of grant.
1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.
/s/ Michael Alrutz, Attorney-in-Fact
2023-01-19